Human liver cancer research currently lacks in vitro models that can faithfully recapitulate the pathophysiology of the original tumor. We recently described a novel, near-physiological organoid culture system, wherein primary human healthy liver cells form long-term expanding organoids that retain liver tissue function and genetic stability. Here we extend this culture system to the propagation of primary liver cancer (PLC) organoids from three of the most common PLC subtypes: hepatocellular carcinoma (HCC), cholangiocarcinoma (CC) and combined HCC/CC (CHC) tumors. PLC-derived organoid cultures preserve the histological architecture, gene expression and genomic landscape of the original tumor, allowing for discrimination between different tumor tissues and subtypes, even after long-term expansion in culture in the same medium conditions. Xenograft studies demonstrate that the tumorogenic potential, histological features and metastatic properties of PLC-derived organoids are preserved in vivo. PLC-derived organoids are amenable for biomarker identification and drug-screening testing and led to the identification of the ERK inhibitor SCH772984 as a potential therapeutic agent for primary liver cancer. We thus demonstrate the wide-ranging biomedical utilities of PLC-derived organoid models in furthering the understanding of liver cancer biology and in developing personalized-medicine approaches for the disease.
Primary liver cancer (PLC) is the second most lethal malignancy worldwide, and incidence rates are rising, mainly owing to an increase in associated risk factors such as diabetes or obesity 1, 2 . The majority of PLC cases are classified into either hepatocellular carcinoma (HCC) or cholangiocarcinoma (CC) 3 . There is also a combined hepatocellular-cholangiocarcinoma (CHC) subtype, which accounts for 0.4% to 14.2% of all PLCs 4 . Although HCCs and CCs are easily distinguishable by their histological appearance 2, 5 and genetic and transcriptional landscapes 6 -CHC shares features of both 7 -PLC is a complex entity overall. This renders each case of the disease unique and in need of personalized treatment.
The development of effective treatments for liver cancer has been hindered by a shortage of reproducible human models in whom to assess the efficacy of candidate therapeutic agents 8 . Historically, preclinical models have consisted mainly of genetically engineered mouse models or human tumor-derived cell lines propagated in either 2Dculture or as xenografts in mice [8] [9] [10] . Although 2D-culture has enabled pioneering advances in cancer biology, it fails to recapitulate critical features of a growing tumor in vivo 11 , especially the 3D organization. In addition, CCs have proven difficult to propagate in vitro 12, 13 .
Recent reports of culture systems of primary, nontransformed tissues growing as 3D structures-termed organoids-accurately recapitulate tissue architecture and function. Thus retinal, cerebral, kidney, intestinal and stomach organoids (among others) 14 have already been generated from pluripotent stem cells for the study of human development and disease. In addition, organoids are promising disease models for researchers to use not only to better understand the biology but also to test drug efficacy in vitro, before they move to animal models 15 . Accordingly, mouse and human cancer organoids have been established recently for colon [16] [17] [18] [19] , pancreas 17, 20 and prostate 21 tumors, but not, so far, for liver tumors.
On the basis of our previous work in mouse liver and pancreas organoid cultures 22, 23 , we showed recently that organoid cultures derived from healthy tissues from human liver could be expanded long-term in vitro while having most of their liver functionality and genetic stability preserved over time 24 . Here we demonstrate proof of concept that liver organoid cultures also recapitulate human primary liver cancer in vitro. Hence, we have successfully established organoid cultures from eight individuals with PLC, encompassing three of the most common subtypes of PLC 3 : HCC, CC and CHC. PLC-derived organoids recapitulate the histological architecture, expression profile, genomic landscape and in vivo tumorigenesis of the parental tumor, even after long-term expansion in culture. In addition, we demonstrate the utility of PLC-derived organoids for identifying genes that have prognostic value for PLC and for identifying potential novel therapeutic targets, thus opening up opportunities for drug testing and advances in personalized-medicine approaches.
RESULTS

Liver cancer organoids maintain parental tumor features after long-term expansion in vitro
We have recently established culture conditions for the long-term expansion of human cells derived from healthy liver tissues 24, 25 . Here we sought to selectively expand tumor cells from human PLC tissue by optimizing our established human liver expansion protocol. Surgically resected liver tumor tissue was obtained from untreated individuals with PLC who had no history of viral-mediated hepatitis. Specimens (~1-cm 3 tissue) of the three main PLC subtypes were obtained, and each individual sample was split into four parts that were processed for organoid derivation or histological diagnostic, genomic or transcriptomic analyses (Fig. 1a,b) . We observed that nontumoral contaminating tissue in the samples gave rise to organoids that would quickly outcompete the tumor-derived organoids, presumably owing to differences in genetic stability, as previously suggested 19 . Therefore, to avoid the growth of nontumoral contaminating organoids, we modified our derivation protocol by (i) increasing the timing of tissue digestion, which reduced the yield of nontumoral contaminants; (ii) changing the starting culture conditions using, in addition to the classical isolation medium 24, 25 , a newly defined PLC-derived-organoid isolation medium, consisting of the classical isolation medium 24, 25 without R-spondin-1, Noggin and Wnt3a, but supplemented with dexamethasone and Rhokinase inhibitor, for at least 2 weeks (Fig. 1c) ; and (iii) closely monitoring the developing organoid structures. Particularly, for all samples in the manuscript, we cultured half of the cell suspension in classical isolation medium, and the other half in our tumoroid-specific isolation medium, to ensure the growth of the cultures (Supplementary Fig. 1 and Online Methods). At the first passage, all cultures (healthy and tumor, irrespective of their subtype-of-origin) were transferred to our previously defined "human healthy liver-derived organoids expansion medium" 24, 25 and expanded and maintained in this medium.
Using this novel protocol, we successfully established human PLC-derived organoids from eight different patients with PLC, including poorly to moderately to well-differentiated HCC (n = 3) and CC (n = 3), and combined HCC/CC (CHC; n = 2) ( Fig. 1,  Supplementary Fig. 2a and Supplementary Table 1 ). We found a strong correlation between the derivation success rate (establishment) and the proliferation index of the original tumor. Thus, the efficiency of establishment of organoid cultures was 100% for those samples derived from tumors that contained >5% proliferating cells (n = 3 for HCC; n = 2 for CHC and n = 3 for CC), whereas we did not succeed in deriving organoids from very well-differentiated lesions, with <5% proliferative cells in the original samples (n = 8 for HCC and n = 1 for CC), in agreement with the histological grading of early HCCs 5 (Supplementary Fig. 2b-g and Supplementary Table 1 ).
PLC-derived organoids (henceforth termed 'tumoroids') from all three different subtypes expanded long-term (~1 year) in culture, with a consistent passaging ratio of 1:3-1:4 every 7-10 d. HCC-2, however, stopped growing after ~1 month, owing to fibroblasts outcompeting tumoroid growth, which precluded any downstream analysis. Therefore, we have performed all the down-stream analysis on the remaining seven lines and corresponding patient-derived tissues (HCC-1 and -3; CHC-1_2 and C-1_3) ( Fig. 1d and Supplementary Fig. 2h) .
At the histological level, tumoroids presented patient-specific heterogeneous morphologies, ranging from solid/compact structures (HCC and CHC) to more irregularly shaped cyst-like structures (CC), in contrast to the ordered, homogeneous, cyst-like hollow structure of healthy-liver-derived organoids ( Fig. 1b and Supplementary Fig. 2a) . These morphological features allowed us to distinguish individual samples from each other, both within and between subtypes, even at late passage and after having been cultured for months in the same conditions.
We then sought to determine whether the 3D tumoroids would retain the histological features of the patient-derived tumor tissue. Healthy-liver-derived organoids form single-layered epithelial structures that transition into a pseudo-stratified epithelium upon differentiation (see ref. 24 for details). By contrast, the tumoroids exhibited a different histological and cellular architecture, which recapitulated the histological features of the patient's tissue and tumor subtype. Thus, HCC and CHC tumoroids exhibited a solid, filled 3D structure with HCCs, but not CHCs, also forming pseudoglandular rosettes, typical of HCC 3, 7 . Similarly, CC tumoroids exhibited extensive glandular domains, with carcinoma cells invading the lumen and growing in cribriform structures, as observed in the patient's tissue ( Fig. 1b and Supplementary Fig. 2a ).
Detailed histological and marker analysis of all the patient's tumor tissues revealed that our cultures derived from a moderately to well-differentiated HCC (HCC-1; AFP + /HepPar1 + ), a poorly differentiated HCC (HCC-3; AFP + /HepPar1 − ), a classical combined (CHC-1; AFP ± /HepPar1 + /EpCAM + /mucin + ), a combined with stem cell features (CHC-2; AFP + /HepPar1 + /EpCAM + /mucin − ) and poorly to moderately to well-differentiated CCs (CC-1-3; HepPar1 − / EpCAM + ) ( Fig. 2a,b, Supplementary Fig. 3a-c and Supplementary  Table 1 ) 26 . Subsequent analysis of these subtype-specific markers in the tumoroids revealed that these express the diagnostic markers of their corresponding patient-derived tissue, even after longterm expansion in culture in the same culture conditions. Thus, EpCAM, was highly expressed in all CC (CC-1-3) and CHC (CHC-1-2) tumoroids and in the corresponding patients' tissues, but was absent in HCC tumoroids and tissues ( Fig. 2c and Supplementary  Fig. 3b ). Likewise, AFP-a well-established marker for HCCs and a subset of CHCs 27 , but not expressed in CCs 3,5,28,29 -was highly expressed in both HCC and CHC-2 tumoroids, in agreement with the expression pattern of the original patient's tissue ( Fig. 2c and Supplementary Table 1 ). Remarkably, the transcription factor Sal-like protein 4 (SALL4), an essential embryonic stem cell factor, described for a subset of poorly differentiated HCCs 30, 31 and CHCs 32 , was present only in HCC-3 and CHC-2, both in tumoroids and matching tissues (Supplementary Fig. 3d ).
Overall, these results demonstrate that liver tumoroids both recapitulated and retained the histological characteristics and marker expression of the original tumor tissue and subtype, even after longterm expansion in culture, in the same culture conditions. corresponding parental tissues using genome-wide transcriptomic (RNAseq) analysis. Healthy-liver-derived organoid lines and corresponding tissues were used as additional controls.
Relative transcript abundance (transcripts per million, RPKM) of 15,648 gene transcripts was determined. Principal component analysis (PCA) analysis indicated that both technical and biological replicates (different passages of the same tumoroid line) for each patient were almost identical to each other ( Supplementary  Fig. 4a,b and Supplementary Data Set 1). Therefore, we present the data per patient as the average of all these replicates. A first hierarchical-clustering analysis comparing the gene expression profiles of our tissue samples with publically available PLC cohorts (344 HCC and 31 CC samples) in The Cancer Genome Atlas (TCGA) confirmed that the samples used in this study are representative of the overall population of primary liver cancer ( Supplementary Fig. 4c and Supplementary Data Set 1). Then, we compared the expression profiles of these parental tissues to the corresponding tumoroid lines. Gene expression correlation analysis indicated that each tumoroid line correlated to its corresponding tissue-of-origin, but not with the other subtypes ( Fig. 3a) . Along the same line, organoids and tissue samples grouped by subtype on the PC2 component, whereas the PC1 component accounted for the variance between tissues and tumorderived organoids. Classical HCC and hepatocyte markers 35 , such as AFP or APOH and CC and ductal markers 36 , such as KRT7, were among the genes that contributed the most to the variance in the PC2 component ( Fig. 3b and Supplementary Data Set 1).
When evaluating specific tumoral and differentiation markers, we found that the tumoroids' expression profiles resembled the corresponding matching tissues and subtype ( Supplementary Fig. 4d ). Notably, we found the HCC markers (AFP and GPC3) and hepatocyte markers (ALB, TTR, APOA1, APOE) to be highly expressed in our HCC tumoroids and matching tissue, whereas CC and ductal markers were Figure 1 Patient-derived primary liver cancer organoid cultures expand long-term in vitro while maintaining the histological architecture of the tumor subtype from which they were derived. (a) Experimental design. Healthy (donor-derived) liver tissues, poorly to moderately to well-differentiated hepatocellular carcinoma (HCC), combined hepatocellular-cholangiocarcinoma (CHC) and cholangiocarcinoma samples (CC) were obtained from patients undergoing surgery (patients' information detailed in Supplementary Table 1 ) and were processed as described in Online Methods and among the most downregulated genes. Reciprocally, CC markers such as EPCAM, KRT19 or S100A11 (refs. 2,37-39) were highly expressed in our CC lines and tissues, whereas HCC markers were not expressed or strongly downregulated. The CHC lines shared the expression patterns of both, as expected ( Fig. 2b,c, Fig. 3b Fig. 3c ), whereas AFP was expressed in CHC-2 but not CHC-1, in concordance with the AFP values obtained from the serum of these patients at the moment of resection (compare Fig. 2c and Supplementary Table 1 ).
These results were confirmed by global analysis using gene-set-enrichment analysis (GSEA) of the tumoroid lines and their corresponding parental tissues against 159 published cancer gene sets ( Fig. 3d and Supplementary Data Sets 2 and 3). Thus, for both HCC lines and corresponding tissues, HCC gene sets were the most significantly positively enriched; HCC-1 was associated with gene sets describing HCC with hepatocyte differentiation features (FDR ≤ 0.25, P ≤ 0.05), and HCC-3 was significantly associated with proliferative HCC subclass (FDR ≤ 0.25, P ≤ 0.05) and KRT19-positive HCC subclass (FDR ≤ 0.25, P ≤ 0.12) gene sets, in agreement with the differentiation status of the patient's original tissue ( Fig. 3d and Supplementary Fig. 5c,d) . Conversely, for all CC tumoroids and matching tissues, CC gene sets were the most significantly positively enriched, (FDR ≤ 0.25, P ≤ 0.05) whereas HCC-specific gene sets were significantly downregulated (FDR ≤ 0.25, P ≤ 0.05), as expected ( Fig. 3d) . Similarly, the CHC expression profiles were negatively correlated with HCC-differentiation gene sets, but positively correlated with stem cell-like, proliferation and/or poor-prognosis gene sets ( Fig. 3d,  Supplementary Fig. 5c,d and Supplementary Data Sets 2 and 3). Subsequent analyses confirmed the RNA-seq results, with HCC but not CC tumoroids exhibiting hepatocyte differentiation features (albumin (ALB) and hepatocyte nuclear factor 4-alpha (HNF4a) expression, albumin secretion and production of bile acid in the medium (the later for HCC-1)) ( Supplementary Fig. 5b ,e,f). By contrast, KRT19-a marker for CC, CHC tumors 2,27 and a subset of HCCs 26 -was highly expressed in all CC types (CC-1-3), in both CHCs (CHC-1-2) and in HCC-3-derived tumoroids; it was undetectable, however, in HCC-1, in agreement with the histological subtype, Healthy-1_O HCC-1_O Figure 4 Tumoroids preserve the genetic alterations from the original tumor. (a) Ploidy analysis of tumoroid cultures expanded for at least 2 months in culture. Results are expressed as the percentage of ploidy per number of metaphases counted (at least 21 total). Healthy-liver derived organoids were used as controls. A minimum of two independent experiments were performed. (b) Representative images of organoid metaphases used for the ploidy analysis. Scale bar, 10 µm. (c-e) Whole-exome sequencing analysis of patient's tumor tissues and corresponding tumoroid cultures expanded for <2 months (early passage) or >4 months (late passage) in culture. All variants identified in all samples (21 total; seven patients with three samples each (tissue/early organoid/late organoid)) were used for the global analyses after being filtered for quality control, as detailed in Online Methods). (c) Correlation heat map between the variants identified in PLC tissues (_T) and PLC tumoroids (_O). (d) Proportions of exonic variants across the samples, the six types of SNVs and the indels are represented. (e) Percentage of the six types of SNV, averaged across all samples. Graph represents mean ± s.d. (f,g) A cancer-related set of variants (f) and variants predicted to impair protein function (SIFT score, <0.05 filter) (g) were identified as described in Online Methods. (f) Bar plots indicate the concordance (%) between the cancer-related variants identified in the tumor of origin and the corresponding tumoroids expanded for short term in culture. (g) Damaging coding mutations found in genes already described as mutated in liver cancer (full list is found in Supplementary Data Set 4; spreadsheet 15 details the references). The type of mutation is indicated in the legend. _T, tissue; _O, organoid. expression pattern and gene signature of each patient's tumor tissue ( Supplementary Fig. 5a,b,d) . Moreover, KRT7, a well-established marker for CCs 37 , was expressed only in the CC-derived organoids and corresponding tissues (Supplementary Fig. 5g) .
These results demonstrate that the PLC-derived-organoid culture system faithfully recapitulates and maintains the transcriptomic alterations present in the individual patient's tumor subtype. Given that the different tumor subtypes were all maintained in the same culture conditions, these results suggest that their tumor signatures are intrinsic to the cancer population, and are not substantially modified by the culture conditions.
Tumoroid and organoid cultures enable the identification of potential prognostic biomarkers for primary liver cancer We next sought to investigate whether the tumoroid culture system could represent a valuable resource for identifying previously unknown genes involved in PLC, and/or novel potential biomarkers for PLC, a use not previously described for any patient-derived organoid system. For that, we defined a 'tumoroid signature' list by comparing the similarities between the transcriptomes of all tumoroid lines to healthy-liver-derived organoid lines. Notably, within the top 30 most upregulated genes, we found 19 genes already reported to be overexpressed in PLC, 13 of which were already associated with poor prognosis, whereas the remaining 11 genes had never been reported as associated with PLC ( Fig. 3e,f and Supplementary Data Set 1).
We then performed an in-depth analysis of these top 30 genes by determining their expression patterns and prognostic values in cohorts of individuals with primary liver cancer and healthy individuals from publicly available TCGA databases (for HCC: 374 patients with HCC and 50 healthy individuals; for CC: 31 patients with CC and 8 healthy individuals). Notably, 29 of the top 30 genes were significantly (P ≤ 0.01) overexpressed in patients with cancer as compared to healthy individuals for both cohorts. Importantly, from the 11 novel genes never before associated with liver cancer, four conferred poor-survival prognosis when overexpressed: C19ORF48, UBE2S and DTYMK (for HCC) and C1QBP (for CC). Of note, STMN1, previously associated with HCC but not with CC 40 , also predicted poor survival in the CC cohort ( Fig. 3f-h and Supplementary Data Set 1). Therefore, these results demonstrate that growing primary liver cancer as tumoroids preserves the tumor-cell features at a level that allows for the identification of new genes with prognostic value, and that could potentially be used as prognostic biomarkers for primary liver cancer. Liver tumoroids retain the genetic alterations present in the original tumor tissue PLCs typically present with a high degree of aneuploidy, several copynumber changes, somatic mutations and epigenetic alterations 6 . All the lines that we expanded in culture (HCC, n = 2; CHC, n = 2; CC, n = 3) exhibited multiple chromosomal aberrations consisting of both gains and/or losses of chromosome numbers (Fig. 4a,b) . This was in stark contrast to healthy-liver-derived organoids that stably maintained diploid chromosome numbers in culture, in agreement with our previous observations 24, 41 . To determine whether the different tumoroid lines retain the parent tumor's mutational landscape, we performed whole-exome sequencing (WES) analysis of each line expanded for short (<2 months, early passage) or extended (>4 months, late passage) periods in culture, and compared the results to analyses of the corresponding parent tumor. We generated ~19-Gb-exome DNA-sequencing data from each sample. When comparing the global variant profile, we observed that, on average, ~92% of the variants in each patient's tissue were retained in their paired early tumoroid cultures (<2 months), and >80% even after months of expansion (paired late tumoroid cultures; >4 months) ( Fig. 4c) . Similarly, the analysis of the proportion of exonic variations for both patient's tissue and corresponding cultures confirmed that both single-nucleotide variants (SNVs) and indels in the original tissue are well retained in culture. Additionally, the distribution of base substitutions for both tissues and tumoroids revealed overrepresentation of the T>C/A>G and C>T/G>A transversions, in agreement with the mutational spectrum described for CCs and HCCs 42, 43 (Fig. 4d,e ). Of note, we did not find substantial bias between transcribed and untranscribed strands (Supplementary Fig. 6a) .
Given that we lacked matched germ-line (nontumor tissue) mutational data, to select for cancer-related variants, we filtered for variants present in the Catalogue of Somatic Mutations in Cancer (COSMIC) and excluded polymorphisms by using publically available databases and following the guidelines described in ref. 44 
(see Online Methods).
The majority of the cancer-related somatic variants present in the patient's original tissue were retained in the corresponding tumoroid cultures (~84%). In fact, <16% (in average) were lost between tissue and early tumoroids, thus suggesting that the cultures represent the genetic landscapes of the tumors from the original patients, with little bias of tumoroid cells harboring specific mutations (~0.5% in average) (Fig. 4f) . The total number of deleterious mutations that could affect protein-function ranges from 70 to 294, in agreement with published mutational burdens for HCC and CC tumors 42, 45 ( Supplementary  Fig. 6b and Supplementary Data Set 4) .
Next-generation-sequencing studies have enabled the creation of a detailed map of the genetic alterations present in liver cancer and its subtypes 6 . In agreement with this mutational spectrum, HCC-1 line and corresponding patient tissue exhibited missense mutations in CTNNB1 ( Fig. 4g and Supplementary Data Set 4) , consistently with their significant enrichment in CTNNB1-mutated liver cancer gene-set found in the gene GSEA ( Fig. 3d) and their elevated levels of Wnt target genes (Supplementary Data Set 1) . CHC-2 line harbored a TP53 frameshift variant (L206fs). In addition, we identified an activating mutation in KRAS (KRAS G12D ) in CC-1 and CHC-1 tumoroid lines and matching tissues, but not in the HCC lines, in agreement with the notable enrichment in epidermal growth factor (EGF)-activated gene set for those lines (Supplementary Fig. 6c ) 46 . We also found nonsense mutations and a disruptive deletion in the chromatin-remodeling genes ARID1A (in HCC-3 and CC-1) and ARID2 (in HCC-3), in agreement with previous reports showing that both genes are altered in all subtypes of PLC 47, 48 (Fig. 4g and  Supplementary Data Set 4) . As expected, all lines were devoid of mutations in MAPK1 and MAPK3 (ERK1 and ERK2, respectively), as described for PLC 45 .
Therefore, these results indicate that the PLC tumoroid culture system retained the mutational landscape of the original tumor tissue and faithfully retained the tumor-subtype-specific mutations present in the original sample from which the tumoroids were derived.
Tumoroids recapitulate the histology of the parental tumor and show metastatic potential in vivo To determine whether tumoroids also recapitulate the features of a human primary liver tumor in vivo, we transplanted CC (CC-1-3 lines) and HCC-1 long-term-expanded tumoroids under the skin of immunocompromised mice. Healthy-liver-derived organoids were used as controls (Fig. 5a) . We found tumor outgrowths in the animals engrafted with CC-1_O (29/29), CC-2_O (8/8) and HCC-1_O (24/34), but not when injected with healthy-liver-derived organoids (Healthy-1_O) ( Fig. 5b and Supplementary Fig. 7a,b) . The CCderived tumors exhibited a strong stromal reaction with CC-1_O tumors, forming glands with proliferative cells growing in cribriform structures ( Fig. 5c and Supplementary Fig. 7c ) and CC-2_O exhibiting a more differentiated phenotype (Supplementary Fig. 7d) , reminiscent of the corresponding patient's tumor tissue. Similarly, HCC-1_O derived tumors grew as solid masses with proliferative cells (Supplementary Fig. 7c ) and exhibited pseudoglandular rosettes, as in the patient's tissue (Fig. 5d) . Secondary tumoroids derived from these xenografted tumors exhibited similar chromosome counts and were morphologically and histologically indistinguishable from their parental line (Supplementary Fig. 7e,f) . Hence, this indicated that even after long-term expansion in vitro and transplantation in vivo, expanding primary liver tumors in organoid culture stably preserves the histological architecture of the parent tumor.
Primary liver cancer has been reported to metastasize primarily to the lung and portal lymph nodes 49 . To determine whether our tumuroid models would faithfully recapitulate the liver cancer metastatic phenotype, we injected CC-1_O, derived from a patient with history of metastasis, into the kidney capsules of NOD-scid gamma (NSG) mice. As expected, 100% of the injected mice developed tumors that resembled the original patient tissue (Fig. 5b,e and Supplementary Fig. 7g ). More importantly, in 7/9 injected mice, we found lung metastases, in agreement with the patient's diagnostic at the moment of resection ( Supplementary  Table 1 ), whereas, as expected, healthy-liver-derived organoids (Healthy-1_O) did not generate any metastases (Fig. 5b,f and Supplementary Fig. 7g) .
Overall, these results establish that primary liver cancer-derived organoids accurately model the histological and metastatic features of their parent tumors in vivo, even after long-term expansion in culture.
Liver tumoroids allow for the identification of patient-specific drug sensitivities and uncover ERK as a potential target for primary liver cancer We performed proof-of-concept drug-sensitivity testing in six of the PLC tumoroid lines (HCC-1; HCC-3; CHC-1-2; CC-1-2) to evaluate their capacity for identifying patient-specific sensitivities, and their uses as a platform to inform drug development. As an initial prioritization step, for each tumoroid line, we tested its sensitivity to 29 anticancer compounds, including drugs in clinical use or development. Tumoroids were treated with a dilution series of each compound © 2017 Nature America, Inc., part of Springer Nature. All rights reserved. for 6 d, before cell viability was measured 50 . Drug sensitivity was represented by the area under the dose-response curve (AUC) and by the half-maximal inhibitory concentration (IC 50 ) (Fig. 6a-c and Supplementary Data Set 5). The assay was conducted with technical replicates, and two biological replicates (different passages of the same tumoroid line) per tumoroid were screened independently. There was a positive correlation of biological AUC replicates (R p = 0.79) and IC 50 replicates (R p = 0.73) across the data set. CC-2 was insensitive to all compounds and so was excluded from further analyses.
From our initial prioritization screen, we confirmed drug sensitivity for a subset of compounds using a tumoroid-formation assay, thus validating our screening method. We selected clinically relevant compounds for which differential sensitivities were observed across the tumoroid panel; namely taselisib, gemcitabine, AZD8931, SCH772984 and dasatanib (Fig. 6c,d) . Overall, good agreement between the screening and validation results was observed (Supplementary Fig. 8a) . For instance, taselisib resulted in a growth-inhibitory effect in five of six tumoroids, whereas dasatinib suppressed tumoroid formation only in CC-1 cells; both results are in agreement with our screening results. An exception was for the CC-1 line with AZD8931, in which case we observed variable sensitivity between biological replicates in the prioritization screen (Fig. 6c,d and Supplementary Fig. 8a) .
Overall, tumoroids were resistant to the majority of the compounds, with an IC 50 greater than the maximum screening concentration, although we detected interesting sensitivity to several compounds that demonstrated a correlation between some drug sensitivities and mutational profiles in the tumoroid lines. For instance, HCC-1 harboring mutations in the CTNNB1 gene was resistant to the porcupine inhibitor LGK974, whereas CC-1, a Wnt-dependent tumor (Fig. 1c) , was sensitive to this inhibitor (Fig. 6a-c) . Moreover, EGFR-family inhibition with AZD8931 restricted tumoroid formation in HCC-1 cells (wild type for KRAS), whereas the other lines, and notably, CC-1 and CHC-1 (KRAS mutants), were resistant. Interestingly, we also observed tumoroid sensitivity to gemcitabine, which is used clinically for the treatment of patients with PLC ( Fig. 6a-c) .
Of particular interest was the substantial inhibition of tumoroid formation following the inhibition of ERK1/2 by SCH772984 in HCC-1-3, CC-1 and CHC-1 cells (Fig. 6a-d and Supplementary Fig. 8a) . SCH772984, which selectively inhibited ERK phosphorylation in HCC-1 and CC-1 tumoroids (Supplementary Fig. 8b) , was effective in lines that were insensitive to the BRAF and/or MEK inhibitors in our screen (dabrafenib and drametinib) (Fig. 6c) . The reason for this difference is unclear, although ERK inhibitors have demonstrated activity in cells with acquired BRAF-and MEK-inhibitor resistance 51 .
We note that clinical trials exploring the effects of specific ERK inhibitors for PLC have not been reported thus far. Hence, to further investigate the potential of ERK1/2 inhibition for PLC, we tested the efficacy of SCH772984 at inhibiting tumor growth in vivo. For this purpose, CC-1-and HCC-1-derived tumoroids were transplanted subcutaneously into NSG mice, and, when tumors reached ~100 mm 3 , they were injected intratumorally with either SCH772984 or the vehicle. Remarkably, 2-7 d after the first injection, we observed significant reduction in tumor growth, which lasted for the remainder of the experiment ( Fig. 6e and Supplementary Fig. 8c ). Histological analysis revealed that the tumor mass was necrotic and that the majority of the cells were apoptotic (Fig. 6f, g and Supplementary Fig. 8d) . Western blot analysis confirmed that SCH772984 also selectively inhibited ERK phosphorylation in CC-1 tumors in vivo (Supplementary Fig. 8e) . Thus, in aggregate, our proof-of-concept study demonstrates the application of PLC tumoroids for drug testing in vitro and in vivo, and provides initial evidence that ERK inhibition could have a beneficial therapeutic effect on a subset of individuals with HCC or CC.
Overall, these results indicate that by faithfully retaining the histological, transcriptomic and genomic landscapes of their parent tumor, tumoroid cultures facilitate the prediction of drug sensitivity and/or resistance in a patient-specific manner. Therefore, they provide an important new resource for liver cancer research, and open up new avenues for biomarker discovery and drug testing.
DISCUSSION
The advent of 3D culture systems has made it possible to partially recapitulate the complexity and function of mammalian tissues in vitro, by producing structures in culture that resemble an adult organ and that have been termed "organoids" 14 . We recently demonstrated that gastric, pancreatic and hepatic organoid cultures derived from adult tissues self-renew and differentiate in vitro, into the corresponding cell types of the tissue of origin 14, 15 .
Here we demonstrate proof of concept that primary liver cancer (PLC) tissue grown as organoid cultures (here termed 'tumoroid') faithfully models the genetic complexity of human PLC in vitro. We successfully established cultures from tumors derived from eight individuals with PLC representing the three most common subtypes of the cancer 3 : HCC, CC and CHC. In contrast to any liver cancer cell line grown in 2D, PLC-derived organoids recapitulate the histological architecture and expression profiles of the corresponding parent tumor, even after long-term expansion in the same culture conditions for all subtypes, or upon transplantation into mice.
Notably, they also retain the specific differences between patients as well as between tumor subtypes. We have exploited this aspect here to demonstrate proof of concept that tumor-derived organoid cultures could represent a valuable resource for biomarker discovery, especially for prognostic markers-an application not previously reported for any organoid culture system. We report C19ORF48, UBE2S, DTYMK (for HCC) and C1QBP and STMN1 (for CC) as previously unidentified genes associated with poor prognosis for primary liver cancer. Further studies, however, will be necessary to prove the utility of these genes as prognostic, their relevance as predictive biomarkers and/or their potential direct involvement in the progression of the disease. These results open up novel opportunities for the use of tumor-derived organoids for tumor-marker discovery.
A unique and important feature of the tumoroids is that they maintain the mutational landscape of the patient's original tumor, even after long-term expansion in culture. This is vastly different from existing 2D cell lines, which-although covering the major driver mutations observed in many cancer subtypes 52 -no longer present the patient-specific signature and genetic landscape of the original tumors from whence they were derived, as exemplified by the frequent acquisition of mutations in TP53 in such cell lines 53 . The reasons for these differences are unknown, but it is feasible to speculate that cell-matrix interactions could have an important role. In fact, embedding primary tumoral epithelial cells into an extracellular matrix (ECM) enables the cells to interpret the environment and self-assemble into structures that acquire tissue patterning, comparable to what happens during development and organogenesis. In addition, the cell-matrix interactions established in 3D could prevent anoikis-apoptosis resulting from the detachment from the matrix 54 -of tumoral cells that have not yet acquired all the mutations that they need to survive in a ECMfree milieu; this would facilitate the maintenance of heterogeneous, nonselected cell populations in the culture. Along that line, our results indicate that if specific tumor cells are selected for in the tumoroid © 2017 Nature America, Inc., part of Springer Nature. All rights reserved.
cultures, it might have a minor effect at the population level, given our finding that tumoroids harbour >80% of the cancer-related variants present in the original tissue.
The reproduction of parent-tumor genetic aberrations in a culture setting makes tumoroid lines a potentially valuable resource in screening for drug sensitivity and resistance and in identifying novel players in primary liver cancer or even novel therapeutics as part of a personalized-medicine approach. Our results validate such an approach by (i) demonstrating a correlation between some drug sensitivities and the mutational profile in the tumoroid lines; and (ii) the de novo identification of the ERK inhibitor SCH772984 as a potential novel therapeutic agent for PLC. Future studies aimed at validating the efficacy of ERK inhibition in a bigger collection of tumoroid lines will be required, however, to confirm its therapeutic value for liver cancer.
The lack of an immune system and stromal components represents a limitation of the culture system, especially when aiming at studying tumor cell-stroma and immune interactions. In that regard, patientderived xenografts (PDXs) have proved to be useful models for human cancer, including liver cancer 13, 55 , because they also retain tumor histopathology, including tumor-infiltrating lymphocytes and the stromal component, and global gene expression and methylation profiles of the patient's malignant epithelial cells 56 . However, PDXs experience a low engraftment rate, especially of CCs (5.8% engraftment efficiency, as reported by Cavalloni et al. 13 ); have a long engraftment period (often several months); are expensive and time consuming (establishment and generation of experimental animal cohorts require a long time); and are not tractable for large-scale drug-sensitivity testing 56 . Therefore, we think that the PLC-derived organoid cultures that we present here are complementary and alternative models to liver cancer PDXs. Furthermore, they are suitable for large-scale drug testing, and on a timescale that makes them potentially compatible with personalized-medicine approaches.
In conclusion, the PLC-derived organoids that we present here fulfill all the criteria of a reliable in vitro cancer model, recapitulating all features of three of the most common subtypes of liver tumors, ranging from histological architecture to genetic and transcriptomic traits, and they are amenable as a platform for drug screening. With a short timescale from establishment to drug testing, this novel in vitro primary liver cancer system thus makes hitherto inaccessible possibilities for predicting patient-specific drug responses and creating personalized à la carte therapies into a reality.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. . All patients provided informed consent. Samples were procured, and the study was conducted under Institutional Review Board approval before tissue acquisition. Samples were confirmed to be tumor or normal on the basis of histopathological assessment. The diagnosis of each case was confirmed on routine H&E-stained slides by an independent histopathologist. For each tumor specimen, samples were split into four parts and processed for histology, RNA and DNA isolation, or dissociated and processed for organoid culture.
isolation and culture of human liver healthy and tumoral organoids. Healthyliver-derived organoids were isolated and cultured using our previously described method 24, 25 , whereas tumor-derived organoids (tumoroids) were isolated by adapting this method as follows. Briefly, one-quarter of the patient-derived or healthy-donor specimen (~0.25-1 cm 3 ) was minced and incubated at 37 °C with the digestion solution. Incubation was performed for 30 min to 1 h for healthy donor tissue (as described in ref. 24 ). Patient-derived tissue digestion was left for 2-5 h to overnight (O/N) according to the degree of liver fibrosis, which was evaluated on a patient-specific basis by visual inspection under a stereomicroscope, as well as according to the resistance of the tissue to be minced. For patient-derived tissue, after 2-5 h digestion, the digestion preparation was visually inspected, and either digestion was stopped or, if a significant part of the original tissue was still underdigested (>50% of starting material, depending on the fibrotic status of the tissue), the preparation was left O/N at 37 °C in the digestion solution to get a good yield of tumoral cells. This increase in the digestion times as compared to healthy tissue (from 2 h to O/N) facilitated a reduction in the number of viable healthy contaminating duct cells. In all cases, the digestion was stopped once no pieces of tissue were left, and the suspension was then filtered through a 100-µm nylon cell strainer and spun for 5 min at 300-400g. The pellet was washed in cold Advanced DMEM/F12 (GIBCO), and then mixed with BME (Basement Membrane Extract, Type 2, Pathclear). 2,000-5,000 cells were seeded per well in a 24-multiwell plate. After BME had solidified, half of the wells obtained for each sample were cultured in the classical human liver organoid isolation medium (Advanced DMEM/F12 supplemented with 1% penicillin/streptomycin, 1% Glutamax, 10-mM HEPES, 1:50 B27 supplement (without vitamin A), 1:100 N2 supplement, 1.25-mM N-acetyl-l-cysteine, 10% (vol/vol) Rspo-1 conditioned medium, 30% (vol/vol) Wnt3a-conditioned medium, 10-mM nicotinamide, 10-nM recombinant human (Leu15)-gastrin I, 50 ng/ml recombinant human EGF, 100 ng/ml recombinant human FGF10, 25 ng/ml recombinant human HGF, 10 µM forskolin, 5 µM A8301, 25 ng/ml Noggin and 10-µM Y27632, as described in ref. 24 ). The other half were cultured in a tumoroid-specific isolation medium (classical human liver organoid isolation medium without Noggin, Rspo-1 and Wnt3a-conditioned media, but supplemented with 3-nM dexamethasone (Sigma-Aldrich). Thus, the tumoroid isolation medium contained: Advanced DMEM/F12 supplemented with 1% penicillin/streptomycin, 1% glutamax, 10-mM HEPES, 1:50 B27 supplement (without vitamin A), 1:100 N2 supplement, 1.25-mM N-acetyl-l-cysteine, 10-mM nicotinamide, 10-nM recombinant human (Leu15)-gastrin I, 50 ng/ml recombinant human EGF, 100 ng/ml recombinant human FGF10, 25 ng/ml recombinant human HGF, 10 µM forskolin, 5 µM A8301, 10 µM Y27632 and 3 nM dexamethasone). It is important to always culture half of the sample in classical isolation medium and half in our tumoroid-specific isolation medium, to ensure growth of the cultures. For instance, CC-1 patient-derived material grew only in classical isolation medium because it requires Rspo-1 to grow. For this line, however, we enriched for the tumoroids by hand-picking out contaminating healthy organoids (as described in Supplementary Fig. 1) .
Afterward, isolation medium was changed twice a week. For healthy donorderived organoids, isolation medium was changed to 'human healthy-liver-derived organoids expansion medium' after 1 week in culture (see composition below). For tumoroids, isolation medium (classical or tumoroid specific) was maintained until the first split. For tumoroid-culture establishment, after 2-3 weeks in culture (depending on the sample), the growing structures were visually inspected and, if required, contaminating healthy organoids were handpicked to prevent these from outgrowing the tumoroid structures. Upon the attainment of dense culture (healthy-liver-derived organoids (1-2 weeks after isolation) and tumor-derived organoids (2-3 weeks after isolation) were passaged by mechanical dissociation into small fragments through trituration with a glass Pasteur pipet, and transferred to fresh matrix in the previously defined 'human healthy liver-derived organoids expansion medium' 24, 25 : Advanced DMEM/F12 supplemented with 1% penicillin/streptomycin, 1% glutamax, 10-mM HEPES, 1:50 B27 supplement (without vitamin A), 1:100 N2 supplement, 1.25-mM N-acetyll-cysteine, 10% (vol/vol) Rspo-1 conditioned medium, 10-mM nicotinamide, 10-nM recombinant human (Leu15)-gastrin I, 50 ng/ml recombinant human EGF, 100 ng/ml recombinant human FGF10, 25 ng/ml recombinant human HGF, 10 µM forskolin and 5-µM A83-01) 24 . Expansion medium was changed twice a week, and cultures were split upon the attainment of dense culture.
All cultures were tested every month for mycoplasma using the 'PCR Mycoplasma Test kit I/C' kit from Promega, in accordance with the manufacturer's instructions.
To prepare frozen stocks, all organoid cultures were dissociated and mixed with recovery-cell-culture freezing medium (GIBCO) and frozen following standard procedures. When required, the cultures were thawed using standard thawing procedures and cultured as described above. For the 3-4 d (organoids) or first 2 weeks (tumoroids) after thawing, the culture medium was supplemented with Y-27632 (10 µM). Organoid pictures were taken using either a Leica M80 stereoscope and Leica MC170 HD camera or with an inverted microscope Leica DMIL and Leica DFC 450C camera.
Histology and staining. Tissues and organoids were fixed for 24 h or 0.5 h respectively, in 10% neutral-buffered formalin (Sigma-Aldrich) at room temperature, and then embedded in paraffin as follows: briefly, tissues were processed through a graded-ethanol series followed by xylene, and then embedded in paraffin, cut at 5 µm and stained (H&E and immunohistological staining). For immunofluorescence experiments, fixed organoids were rehydrated with PBS following formalin fixation. For immunohistological staining, paraffin slides were deparaffinized and subjected to antigen retrieval using citrate sodium solution (pH 6). To reduce background nonspecific staining and permeabilize the sample, slides were incubated with a 1% BSA, 0.5% Triton in TBS solution for 1 h. Primary antibodies (listed in Supplementary Data Set 6) were then applied at appropriate dilutions for overnight at 4 °C (see Supplementary Data Set 6 for details). Endogenous peroxidase activity was blocked for 15 min in a 3% hydrogen-peroxide/methanol buffer. Detection of bound antibody was accomplished with the BrightVision Ultimate kit (Immunologic). Briefly, slides were washed in TBS and incubated with a secondary antibody-HRP conjugate for 1 h at room temperature and finally developed with 3,3′-diaminobenzidine (DAB) for 5 min, counterstained with hematoxylin, and mounted with DPX (Sigma-Aldrich). Slides were also stained in the absence of primary antibodies to evaluate nonspecific secondary-antibody reactions. For TUNEL assay, Click-iT Plus TUNEL kit (Molecular Probes, Life Technologies) was used in accordance with the manufacturer's instructions. Pictures were taken using a Leica microscope DM 4000 microscope and DFC 450 camera (Leica). For whole-mount immunofluorescence staining, organoids were processed as described in refs. [23] [24] [25] . Briefly, organoids were incubated with primary antibodies over two or three nights at 4 °C, washed in PBS, and revealed by incubation with a secondary antibody conjugated to a fluorophore. Nuclei were stained with Hoechst33342 (Molecular Probes, Life Technologies). Confocal images were captured on a Leica SP5 inverted confocal microscope (Leica).
Ki67 index.
Each tumor slide stained for Ki67 was manually scanned with a microscope at 10× objective, and the area of greatest Ki67 positivity (hot spot) was selected for photographing. At least 1,000 total tumoral cells were counted on a total of two independently stained slides per patient. Pictures were taken using a Leica microscope DM 4000 microscope and DFC 450 camera (Leica) and Ki67negative and Ki67-positive cells were then counted using ImageJ 'cell counter' plug-in. Light brown or pale staining nuclei were ignored during counting.
Karyotyping. Karyotyping was performed as previously described 24 . Briefly, cultures were incubated with 0.1 ug/ml Karyomax Colcemid (Gibco). After 24 h, organoids were harvested and dissociated using TrypLE (Gibco). Cells were incubated with KCL 0.0075 M hypotonic solution for 10 min, fixed in methanol: acetic acid (3:1) and dropped on a microscope slide for visualization. Nuclei were mounted and stained using Vectashield with DAPI (Vector Labs). A minimum of 15 metaphases per sample were counted.
Sequencing and analysis. For both RNA sequencing (RNA-seq) and wholeexome sequencing (WES), low-quality reads were filtered (<Q20), followed by the trimming of low-quality bases from the ends of the reads (<Q20). Adaptors were also removed using cutadapt. rna sequencing. RNA was isolated from organoids using RNeasy mini kit (Qiagen) following the manufacturer's instructions. RNA libraries were prepared for sequencing using the Smartseq2 method. RNA sequencing was performed using Illumina HiSeq sequencer (50-bp single-end reads and 10 million-20 million reads were generated for each sample). Reads were aligned with Tophat (v2.1.0) 57 to the GRCh38.82 genome, using the corresponding .gtf file for exon positions. Counts were generated using featureCounts (v1.5.0-p1) 58 . Only protein-coding genes, long intergenic noncoding RNAs, processed transcripts and misc. RNA were kept for further study. Normalized counts were created using DESeq2 (ref. 59) and RPKMs using edgeR's function (edgeR). The technical and biological replicates (different passages) were merged. Healthy growing in organoids expansion and differentiation medium and corresponding tissues were used as additional controls.
To assess the concordance of tissues with organoids, genes were filtered and Pearson's correlation coefficient was calculated pairwise between tissues and organoids. The correlation matrix was then z-scored. The principal components for several subgroups of the samples were calculated from the normalized DESeq counts, and the first two (PC1, PC2) were plotted. We then analyzed the top 100 genes with the highest loadings across PC2, which separated the samples by subtype. Functional analysis was split across the three subtypes, and genes were excluded in each unless healthy or tumor samples had RPKM values greater than 1. To generate a statistic for tumoral tissue samples, the log 2 fold change (FC) of each tumoral tissue was divided by the mean of the healthy tissues. To generate a statistic for HCC tumoroid samples, two log 2 fold changes (FC) were calculated: the first was HCC organoid divided by the mean of healthyliver-derived organoid and the second was HCC tissue divided by the mean of the healthy tissues. Then, the mean or minimum was then taken of these two ratios-whichever had a lower absolute value. The same statistic was generated for CHC and CC tumoroids using the mean healthy tissue instead of healthyliver-derived organoid as a baseline for the first fold change. These statistics were then used for pre-ranked GSEA using GSEA software (http://www.broadinstitute.org/gsea/) 60 . 159 gene sets were used for running the GSEA. These gene sets were obtained after curation of the publically available C2 MSigDB collection for "LIV", "HEPT" and "STEM" key words and completed by available liver cancer gene set described in literature (see Supplementary Data Set 2 and 3) to select a relevant list of gene sets associated with liver cancer and stemness. 1,000 permutations were used to calculate P value. A tumoroid signature was identified by finding the genes with the highest FC when dividing the minimum expression value, in RPKMs, over all tumoroid samples by the mean of the expression of healthy-liver-derived organoids in differentiation medium. Several aspects of the genes defining the tumoroids' signature were annotated: the description of their corresponding proteins was downloaded from Uniprot 61 , and their relevance to disease was obtained by retrieving the Disease Ontology terms (using the R package dnet v1.0.10 62 ).
WeS. DNA from tumor tissue and matched tumoroid lines was extracted using DNeasy Blood & Tissue Kit (Qiagen), according to the manufacturer's protocol. Point mutations and short indels were called in a procedure composed of several steps as follows: (i) Reads were aligned to the UCSC hg38 genome using Bowtie2 (v2.2.6) 63 , and the output was preprocessed for variant calling by marking duplicates with Picard (v1.113) (http://broadinstitute.github. io/picard/) followed by indel realignment with the GATK toolkit (v3.7) 64 . SNPs and indels were called with Varscan (v.2.3) 65 . (ii) We identified and selected the variants with the following parameters: base quality ≥15 (Phred score), read depth ≥15 and annotated by SNPEff 66 as not 'intergenic.' (iii) We removed variants on alternate haplotypes. (iv) Analysis was then split between patients. For each, there were three samples, the tissue and the corresponding tumoroids expanded for <2 months (early) or >4 months (late). If a variant was called in the 'early' sample, a variant was added into the tissue if its pileup showed evidence of the same variant at that position. Moreover, if a variant was called in the 'late' sample, a variant was added in the tissue and early sample if their pileups both showed evidence of the same variant at that position. Figure 6 are based on this final list of variants. To assess concordance, overlaps of variants found in tissue and early and late tumoroids were calculated in and between cancer types using GATK (v3.7). The mutation spectrum was examined in each sample in both nontranscribed and transcribed strands and then summarized by representing the average proportion across all samples. A cancer-related set of variants was defined by adding the following filtering steps: (v) to filter out polymorphisms and nondamaging variants, we exclude variants that had reads supporting variations of ≥2 in our sequenced healthy samples (Healthy-1_Tissue and _Organoid; Healthy-2_Organoid) and/or were included in dbSNP (common _ no _ known _ medical _ impact _ 20170801.vcf) 67 and/or with a frequency of >0.01 in ExAC database 68 . To select for cancer-related variants, we then (vi) filtered for the variants present in COSMIC (v76) 69 and (vii) filtered out synonymous and intronic variants. The variant positions with their associated effects were annotated with SnpEff 66 . Resultant variants were used for the Figure 4f. (viii) Finally, we selected the mutations that were highly predicted to impair the function of the corresponding encoded proteins by filtering for coding mutations and using SIFT 70 to predict the deleterious (SIFT score, <0.05) impact of missense and structural variants. A summary of the concordant (tissue/ early/late) coding variants obtained per patient is provided in Supplementary Data Set 4, and this final list of variants was used for Supplementary  Figure 6b For the hierarchical-clustering analysis, our sequencing data were processed according to the GDC mRNA quantification analysis pipeline to obtain FPKM values comparable to the ones from the TCGA cohorts. The hierarchical clustering used the Euclidean distances between samples on the basis of the top 500 expressed genes, and was performed using hclust in R and plotted using the dendextend R package 71 . Healthy samples, samples not annotated for the stage of the disease and recurrent disease samples were excluded from the analysis.
For the survival analysis, we examined the expression of the top 30 genes of the tumoroid signature, in both TCGA-LIHC and TCGA-CHOL cohorts. From the FPKM values of tumoral and control samples, we generated base-R boxplots (R's default boxplot code) and assessed the significance between both groups by unpaired two-tailed Student's t-test. Survival plots were created using the R package TCGAbiolinks (v2.2.10) 72 and by splitting, per gene, the tumor samples into high-and low-expression groups. The median of all samples was used as the threshold, and significance for differences between the two groups was assessed by a log-rank test.
Quantitative rT-pCr. Total RNA was extracted from organoid cultures or freshly isolated tissues using RNeasy mini kit (Qiagen), in accordance with the manufacturer's instructions. cDNA was synthesized using 0.5 µg of total RNA and a M-MLV Reverse Transcriptase kit (Promega). cDNA was amplified with iTaq Universal SYBR Green Supermix (Bio-Rad) and using gene-specific primers described in Supplementary Data Set 6. All targets were amplified (40 cycles) on a CFX96 Touch Real-Time PCR Detection System (Bio-Rad). Data were analyzed using Bio-Rad CFX manager. Expression levels were normalized to the expression of the housekeeping gene HPRT.
Functional in vitro studies. Functional studies were performed in collected supernatant or in whole organoids. To assess albumin production, culture medium was collected 1 week after the last medium change, and albumin levels were assessed using an Albumin ELISA kit (Assay Pro) according to the manufacturer's instructions. Values were corrected for the time and cell number. The concentration of total bile acid was established using a Total Bile Assay kit (Cell Biolabs), according to manufacturer's instructions on supernatant obtained after the sonication of whole organoids in PBS.
Organoid-formation assay. To assess the organoid formation efficiency in classical versus tumoroid isolation medium, pictures of all full drops of BME obtained per patient were photographed using a Leica M80 stereoscope 2-3 weeks after isolation (depending on the sample), and all viable tumoroid structures were counted.
For the drug-sensitivity assays, organoids were dissociated into 2-5 cell clumps by enzymatic dissociation with TrypLE (Life Technologies). Then, cell-viability assays were conducted by plating 500 clumps per well of a 48well cell-culture plate in 250 µl of expansion medium supplemented with 0.5 µM Gemcitabine (Actavis), 5 µM of AZD8931 (Selleckchem), 10 µM of SCH772984 (Selleckchem), 2 µM dasatinib (Selleckchem), 10 µM of taselisib (Selleckchem), or vehicle (DMSO) control. All conditions were supplemented with Rho-kinase inhibitor Y-27632 (Sigma-Aldrich). The concentration selected for each compound was based on the cell-viability data from our laboratory, the results from the screening or the literature. Medium was changed three times a week for 3 weeks. Viable cells were assessed by their ability to generate organoid de novo. Representative pictures of the viability result were taken 2-3 weeks after starting the treatment. All cell-viability experiments were conducted in triplicate in at least two independent experiments (biological replicates = different passages).
Drug screening. Organoid-viability assays were conducted as previously described 19, 50 . Briefly, 8 µl of ~7 mg/ml BME-2 was dispensed into 384well microplates and allowed to polymerize. Organoids were mechanically dissociated by pipetting before being resuspended in 2% matrigel/growth media (15,000-20,000 organoids/ml) and dispensed into 384-well plates. The following day, a concentration dilution series of each compound was dispensed using liquid-handling robotics, and cell viability was assayed using CellTiter-Glo (Promega) after 6 d of drug incubation. An experimental concentration range was calculated for each compound using a seven-point half-log dilution series of the highest maximal concentration. The maximal concentration of each compound can be found in Supplementary Data Set 5. Screens were performed in technical (same screening run) and biological duplicates (different passage), and all screening plates were subjected to stringent quality-control measures, and a Z-factor score comparing negativeand positive-control wells was calculated. Dose-response curves were fitted to the luminescence signal intensities using a method previously described 73 . Variation in replicates was greater than in similar screens performed in colorectal tumoroids, and was likely due to the large size of HCC tumoroids, leading to uneven distribution in screening wells 19, 50 . Compound and screening concentrations are provided in Supplementary Data Set 5. The range of concentrations selected for each compound was based on data of concentrations inhibiting relevant target activity and cell viability in vitro, on the basis of data from our laboratory or literature.
Mouse xenograft studies.
All mouse experiments have been regulated under the Animals (Scientific Procedures) Act 1986 Amendment Regulations 2012 following ethical review by the University of Cambridge Animal Welfare and Ethical Review Body (AWERB) and have been performed in accordance with the Home Office license awarded to M.H. For subcutaneous grafts, 1 million-cell suspensions were prepared in PBS-0.1% BSA (CC and healthy-liverderived organoid lines) or in Advanced DMEM/F12 (GIBCO) 1% glycosil (ESI-BIO) further supplemented with 50ng/ml each of HGF and VEGF (HCC and healthy-liver-derived organoid lines) and were injected into both flanks of male NSG-NOD scid-mice (Charles River). Visible tumors developed in approximately 2-4 weeks (CC organoid lines) and 4-6 months (HCC-1 organoid line). Mice were culled when the tumor reached limit end-point (size or ulceration). For the kidney-capsule graft, cell-line suspensions were prepared in Advanced DMEM/F12 (GIBCO) with BME2 (7 mg/ml) and 500,000 cells were implanted under the renal capsule of NSG mice. These mice were then culled at different time points (0.5, 1, 2 and 3 months) and kidney and lung tissues were harvested to assess the growth and the metastatic potential of the grafted cells.
To assess the efficiency of the ERK inhibitor SCH772984 in vivo, mice with established subcutaneous tumors were randomized to drug treatment by splitting size-matched tumors into two groups (SCH772984/vehicle). Treatments (SCH772984 at 120 µg/tumor, or an equal volume of vehicle (25%DMSO-30%PEG300 in DD water) were administered by intratumoral injection daily for 20 (CC-1 tumoroid line) or 15 (HCC-1 tumoroid line) d. Tumor sizes were measured three times a week after the first week of treatment using a caliper and volumes were calculated by applying the formula v = 0.5 × L × w × h, where v is volume, L is length, w is width and h is height. Investigators performing tumor measurements were blinded to treatment groups. Histological analyses of the tumors from both CC-1 and HCC-1 lines were performed at 24 and 25 d after treatment initiation, respectively.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed). n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
